Severe asthma

An update for 2019

Adam D. Highley, Craig Cookman, Lee E. Morrow, Mark A. Malesker

Research output: Contribution to specialist publicationArticle

Abstract

Asthma is a common respiratory disorder, and the presentation of patients with acute, poorly controlled asthma remains a clinical challenge. In current guidelines, severe asthma represents a subset of difficult-to-treat asthma that, despite treatment of contributing factors and patient compliance with optimized therapy, remains uncontrolled, or asthma that worsens when high-intensity therapy is decreased. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids plus a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting muscarinic, a leukotriene antagonist, and biologics.

Original languageEnglish (US)
PagesHS2-HS7
Volume44
No7
Specialist publicationU.S. Pharmacist
StatePublished - Jan 1 2019

Fingerprint

Bronchodilator Agents
Adrenal Cortex Hormones
Asthma
Leukotriene Antagonists
Drug therapy
Biological Products
Cholinergic Agents
Patient Compliance
Therapeutics
Guidelines
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Cite this

Highley, A. D., Cookman, C., Morrow, L. E., & Malesker, M. A. (2019). Severe asthma: An update for 2019. U.S. Pharmacist, 44(7), HS2-HS7.

Severe asthma : An update for 2019. / Highley, Adam D.; Cookman, Craig; Morrow, Lee E.; Malesker, Mark A.

In: U.S. Pharmacist, Vol. 44, No. 7, 01.01.2019, p. HS2-HS7.

Research output: Contribution to specialist publicationArticle

Highley, AD, Cookman, C, Morrow, LE & Malesker, MA 2019, 'Severe asthma: An update for 2019' U.S. Pharmacist, vol. 44, no. 7, pp. HS2-HS7.
Highley AD, Cookman C, Morrow LE, Malesker MA. Severe asthma: An update for 2019. U.S. Pharmacist. 2019 Jan 1;44(7):HS2-HS7.
Highley, Adam D. ; Cookman, Craig ; Morrow, Lee E. ; Malesker, Mark A. / Severe asthma : An update for 2019. In: U.S. Pharmacist. 2019 ; Vol. 44, No. 7. pp. HS2-HS7.
@misc{f9c39f1aa7254e23a674e985d24e0ec2,
title = "Severe asthma: An update for 2019",
abstract = "Asthma is a common respiratory disorder, and the presentation of patients with acute, poorly controlled asthma remains a clinical challenge. In current guidelines, severe asthma represents a subset of difficult-to-treat asthma that, despite treatment of contributing factors and patient compliance with optimized therapy, remains uncontrolled, or asthma that worsens when high-intensity therapy is decreased. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids plus a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting muscarinic, a leukotriene antagonist, and biologics.",
author = "Highley, {Adam D.} and Craig Cookman and Morrow, {Lee E.} and Malesker, {Mark A.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "44",
pages = "HS2--HS7",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Severe asthma

T2 - An update for 2019

AU - Highley, Adam D.

AU - Cookman, Craig

AU - Morrow, Lee E.

AU - Malesker, Mark A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Asthma is a common respiratory disorder, and the presentation of patients with acute, poorly controlled asthma remains a clinical challenge. In current guidelines, severe asthma represents a subset of difficult-to-treat asthma that, despite treatment of contributing factors and patient compliance with optimized therapy, remains uncontrolled, or asthma that worsens when high-intensity therapy is decreased. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids plus a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting muscarinic, a leukotriene antagonist, and biologics.

AB - Asthma is a common respiratory disorder, and the presentation of patients with acute, poorly controlled asthma remains a clinical challenge. In current guidelines, severe asthma represents a subset of difficult-to-treat asthma that, despite treatment of contributing factors and patient compliance with optimized therapy, remains uncontrolled, or asthma that worsens when high-intensity therapy is decreased. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids plus a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting muscarinic, a leukotriene antagonist, and biologics.

UR - http://www.scopus.com/inward/record.url?scp=85071622702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071622702&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - HS2-HS7

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -